Based on our own experience, in accordance with two other case reports in the literature, subsequent treatment with RET-TKI after one TKI may represent a potential therapeutic possibility for those patients affected by RET-rearranged NSCLC brain metastases and who received the first TKI at a reduced dosage due to adverse events. The gene discussed is RET; the disease is non-small cell lung carcinoma.